 Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to Genmab AS NASDAQ: GMAB and its partner Janssen Biotech Incs Darzalex daratumumab subcutaneous for amyloidosis. The opinion is for daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone to treat adult patients with newly diagnosed systemic light-chain amyloidosis. 